Last reviewed · How we verify
Innovaderm Research Inc. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
3 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Eucerin | Eucerin | marketed | Other | |||
| Adalimumab Every Week | Adalimumab Every Week | phase 3 | TNF-alpha inhibitor | TNF-alpha (Tumor Necrosis Factor-alpha) | Immunology | |
| Adalimumab every other week | Adalimumab every other week | phase 3 | TNF-α inhibitor | TNF-α (tumor necrosis factor-alpha) | Immunology | |
| Placebo / Xeomin | Placebo / Xeomin | phase 3 | Botulinum toxin type A | SNARE complex (synaptosome-associated protein) | Neurology / Aesthetics |
Therapeutic area mix
- Immunology · 2
- Neurology / Aesthetics · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Alvotech Swiss AG · 2 shared drug classes
- Abbott · 2 shared drug classes
- AbbVie (prior sponsor, Abbott) · 1 shared drug class
- Altuğ Güner · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Asan Medical Center · 1 shared drug class
- ATGC Co., Ltd. · 1 shared drug class
- ASIS Corporation · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Innovaderm Research Inc.:
- Innovaderm Research Inc. pipeline updates — RSS
- Innovaderm Research Inc. pipeline updates — Atom
- Innovaderm Research Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Innovaderm Research Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/innovaderm-research-inc. Accessed 2026-05-16.